Key Highlights

  • The quarterly net loss widened to USD 46.6 million, or USD 0.81 per share, from USD 36.8 million, or USD 0.97 per share, in the same period last year.
  • R&D spending increased to USD 45.6 million from USD 32.5 million, and G&A rose to USD 14.1 million from USD 8.2 million.
  • The company reports USD 1.2 billion in cash, equivalents and investments as of September 30, 2026, which it considers enough to support operations through 2030.
  • Upcoming top-line data from the Phase 2 MoMeNtum study of multifocal motor neuropathy, which now includes 46 patients, are anticipated in December 2026.

Trial Expenses Push the Quarterly Loss Wider

Dianthus Therapeutics (NASDAQ:DNTH) filed its Quarterly Report on November 4, 2026. The clinical-stage company is advancing claseprubart, an under-the-skin antibody for autoimmune and neuromuscular conditions, together with two earlier programs, DNTH212 and DNTH312. License income came to USD 1.2 million, compared with USD 0.4 million, and was linked to reimbursable trial expenses. Operating costs grew to USD 59.7 million from USD 40.7 million, with stock-based pay making up much of the rise. Interest and Investment Earnings jumped to USD 12.1 million from USD 3.7 million thanks to bigger cash holdings, cushioning the loss. Nine-month net loss reached USD 137.7 million, or USD 2.56 per share, up from USD 97.9 million, or USD 2.68 a year earlier.

Claseprubart Milestones and Upcoming Study Timelines

The Phase 3 EMERGE study in generalized myasthenia gravis began in June 2026, with top-line results expected during the second half of 2028. In the Phase 3 CAPTIVATE study for chronic inflammatory demyelinating polyneuropathy, an interim review of the first 40 Part A patients produced a 75% response rate, measured against a 50% or higher target. Management now estimates fewer than 200 open-label patients will be needed to randomize 128 responders. Part A readouts are due by the end of 2027, and Part B by the end of 2028. Enrollment in the Phase 2 MoMeNtum study, which surpassed its 36-patient goal, finished in August 2026, and a Phase 3 study in that disease is set for 2027. The FDA granted Orphan Drug Designation to claseprubart for myasthenia gravis on May 1, 2026. Enrollment in that study was complete by August 2026, ahead of the December readout.

A USD 500 Million At-the-Market Program and Dilution Exposure

Capital raised so far totals USD 1.0 billion through public offerings, USD 423.5 million through private placements and USD 200.0 million through an earlier at-the-market program, which included 3,632,534 shares sold. On September 18, 2026 the company entered a fresh agreement permitting sales of up to USD 500 million, a structure that releases shares gradually and can dilute investors. The company says further funding will be necessary, and a shortfall could postpone or halt trials. The accumulated Deficit stands at USD 474.4 million, and management warns that quarterly losses may vary widely.

Where Things Stand

Probably, by the company's own reckoning, though the plan depends on assumptions that could turn out wrong. Dianthus Therapeutics (NASDAQ:DNTH) has USD 1.2 billion against a USD 46.6 million quarterly loss and states that this covers operations into 2030. Spending is rising as Phase 3 programs expand, which makes the runway sensitive to trial costs. The December 2026 MoMeNtum readout is the nearest catalyst, followed by CAPTIVATE Part A by the end of 2027.